Stocks and Investing
Stocks and Investing
Wed, October 19, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Danielle Brill Initiated (XENE) at Buy and Held Target at $52 on, Oct 19th, 2022
Danielle Brill of Raymond James, Initiated "Xenon Pharmaceuticals Inc." (XENE) at Buy and Held Target at $52 on, Oct 19th, 2022.
Danielle has made no other calls on XENE in the last 4 months.
There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Danielle's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Danielle
- Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $49 on, Tuesday, October 11th, 2022
- Jason Gerberry of "B of A Securities" Initiated at Strong Buy on, Monday, August 29th, 2022
- Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $46 on, Thursday, August 11th, 2022
- Tessa Romero of "JP Morgan" Initiated at Buy and Held Target at $55 on, Thursday, July 21st, 2022
- Laura Chico of "Wedbush" Maintained at Buy with Decreased Target to $41 on, Monday, June 27th, 2022
Contributing Sources